Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry

Our objective is to collect prospective data on cancer subjects who undergo surgery and intraoperative imaging. The registry will include (but not limited to) cancer type, stage, intraoperative challenges to the surgeon, usage and results of intraoperative imaging, and recurrence surveillance.

In this protocol, subjects that receive intraoperative imaging will provide us the opportunity to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed. Also, we will monitor any side effects or potential toxicities that may occur. This data can then be used to predict if a subject is more likely to develop a local recurrence due to missed cancer cells, metastatic lymph nodes or synchronous lesions.

• OTL38 (Drug): Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.
• ICG (Drug): Patients will be given imaging agent 24 hours before surgery to assist in imaging.

Primary outcomes

• Tissue to Background Ratio [2 years]: Enhance ability to detect malignant tissues in situ and ex vivo.

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Adult patients >/= 18 years of age.
* Patients presenting with esophagogastric or bladder cancer.
* Good operative candidate as determined by the treating physician and/or multidisciplinary team.
* Subject capable of giving informed consent and participating in the process of consent.

Exclusion Criteria:

* Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery.
* Vulnerable patient population.

• Sunil Singhal, Principal investigator, University of Pennsylvania